$fractalworks for mac$

$fractalworks for mac$

#FRACTALWORKS FOR MAC MAC#

so they work to setup and maintain connections with as many licensed distributors as they can handle. Manufacturers typically want to maximize the availability of their products to all licensed pharmacies in the U.S. Most manufacturers ship the drugs they make to many of the licensed distributors. pharma supply chain from a typical manufacturer. Now let’s take a magnified look at the immediate view of the supply chain from the perspective of an average drug manufacturer. Of course, the reality is much different–some handling more product and some handling much less than the average–because the sizes of the companies in the supply chain vary widely. If you would take the total volume of drugs that pass through this supply chain in a given year and divide it evenly among each of the entities in each segment you would find that the percent of product that the average distributor handles is much higher than that of the average manufacturer and would be huge compared with that of the average pharmacy. The most striking thing about this view is that it shows how few distributors there are compared with the number of manufacturers and especially compared with the number of pharmacy delivery points. Keep in mind that more than 90% of the volume of drugs passing through the supply chain goes through only three distributors.

$fractalworks for mac$

I estimated the number of pharma distributors based on the list of corporate entities found in the Authorized Distributors of Record (ADR) lists of several large pharma manufacturers found on the internet. Counts for the manufacturers and pharmacy delivery points are from the HDMA (2009). Proportions of the three primary segments of the U.S. Here is a view of the supply chain where the vertical scale shows something closer to the true proportions between those three segments. That view masks so much important complexity that if we were to select a regulatory model or solution based on that view it would be far from ideal. In the debates and discussions over pedigree regulatory models we are used to seeing a view of the supply chain that shows one manufacturer, one distributor and one pharmacy. you will see that there are other characteristics besides data volume per package that need to be considered. The ideal model would minimize the amount of data moved yet always allow each member of the supply chain to check the prior history-the pedigree-of the drugs they are about to buy.Īt a superficial level this appears to be all you need to do, but when you take a closer at the details of how the supply chain actually works in the U.S. pharmaceutical supply chain often centers around how much data for each package of drugs needs to be moved between trading partners as those drugs move down the supply chain from the manufacturer to distributor(s) and ultimately to the pharmacy. The debate over pedigree regulatory models in the U.S.

#FRACTALWORKS FOR MAC MAC#

FractalWorks is available on the Mac App Store (Click on image). This image was created with FractalWorks, a high performance fractal renderer for Macintosh computers.

$fractalworks for mac$

Fractalworks for mac